Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.69 |
| ▸ | DPP8 | Q6V1X1 | 12/20 | 0.56 |
| ▸ | DPP9 | Q86TI2 | 12/20 | 0.56 |
| ▸ | FAP | Q12884 | 11/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15026111 | 0.88 | DPP4 (0.71) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8304076 | 0.85 | DPP4 (0.61) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL3170213 | 0.85 | DPP4 (0.61) | DPP4DPP8DPP9FAPDPP7 | |
| Denagliptin SCHEMBL682185 | 0.82 | DPP4 (1.00) | DPP4DPP8DPP9FAPDPP7 | |
| Denagliptin SCHEMBL18815071 | 0.82 | DPP4 (1.00) | DPP4DPP8DPP9FAPDPP7 | |
| Denagliptin SCHEMBL2552817 | 0.82 | DPP4 (1.00) | DPP4DPP8DPP9FAPDPP7 | |
| Denagliptin SCHEMBL987759 | 0.82 | DPP4 (1.00) | DPP4DPP8DPP9FAPDPP7 | |
| Denagliptin SCHEMBL1035624 | 0.82 | DPP4 (1.00) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL5216061 | 0.81 | DPP4 (0.55) | DPP4DPP8DPP9FAPDPP7 | |
| Denagliptin SCHEMBL3151455 | 0.81 | DPP4 (0.98) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462641-B2 | (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1654226-B1 | (2S,4S)-4-FLUORO-1- 4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL -2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070066677-A1 | (2S,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-I-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof | SMITHKLINE BEECHAM CORPORATION | 2007-03-22 | — | — | US | disclosed |
| EP-1654226-A1 | (2S,4S)-4-FLUORO-1- 4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL -2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SmithKline Beecham Corporation (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005009956-A1 | (2S,4S)-4-FLUORO-1-[4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL]-2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066677-A1 | (2S,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-I-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof | PFAS, TTR, PNN | DPP4 283/4885DPP8 1530/4885DPP9 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.